$OGN Cashflow Statement | Understand Stock

$OGN

$13.75 +$0.01 (0.07%) Close

$OGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows from Operating Activities
Net income
Adjustments to reconcile net income to net cash flows provided by operating activities:
Depreciation
Amortization
Impairment of assets
Acquired in-process research and development and milestones
Accretion and changes in fair value in contingent consideration
Deferred income tax expense (benefit)
Stock-based compensation
Unrealized foreign exchange loss (gain)
Unrealized foreign exchange (gain) loss
Gain on debt repurchase
Impairment of Goodwill
Other
Net changes in assets and liabilities, net of assets acquired
Accounts receivable
Inventories
Other current assets
Trade accounts payable
Accrued and other current liabilities
Due from/due to related party
Income taxes payable
Other
Net Cash Flows Provided by Operating Activities
Cash Flows from Investing Activities
Capital expenditures
Proceeds from sale of property, plant and equipment
Acquired in-process research and development and milestones
Dermavant acquisition, net of cash acquired
Purchase of product rights and asset acquisition
Net Cash Flows Used in Investing Activities
Cash Flows from Financing Activities
Proceeds from debt
Payment of long-term debt issuance costs
Proceeds from short-term borrowings from Merck & Co, Inc.
Repayments of short-term borrowings from Merck & Co., Inc., net
Net consideration paid to Merck & Co. Inc. in connection with the Separation
Net transfers to Merck & Co., Inc.
Employee withholding taxes related to stock-based awards
Dividend payments
Net Cash Flows Used in Financing Activities from Continuing Operations

Net Cash Provided by (Used in) Operating Activities
Net Cash Used in Investing Activities
Net Cash Used in Financing Activities
Net Cash Flows Used in Discontinued Operations
Net Cash Flows Used in Financing Activities
Effect of Exchange Rate Changes on Cash and Cash Equivalents
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Discontinued Operations
Net Decrease in Cash and Cash Equivalents
Cash and Cash Equivalents, Beginning of Period
Cash and Cash Equivalents of Discontinued Operations, Beginning of Period
Less: Cash and Cash Equivalents of Discontinued Operations, End of Period
Cash and Cash Equivalents, End of Period

Comments